Get the latest news, download our reports, watch our interviews and more! Join our mailing list to stay in touch.
encodelp
@encodelp
$OCUP continues to trend up post Famy deal. Seems likely this momentum continues given additional news of Nyxol NDA… https://t.co/nG5WhpdfTN
encodelp
@encodelp
$SLNO trading well today https://t.co/aSLBanujXz
encodelp
@encodelp
$SLNO should be fun to watch in 2023. Randomized withdrawal study reads out 1H23. Co seems confident FDA will accep… https://t.co/HF50EpySML
encodelp
@encodelp
$XENE updates XEN1101 MDD top-line guidance to 3Q23
encodelp
@encodelp
$NVCN low-float medtech trading under cash. The timelines for pivotal data for their refractory angina program are… https://t.co/zXZMrNzlFH
Unlike the sell-side, we will also be active on social media. After we publish our initiation report, subsequent updates and comments on a company will be done predominantly on Twitter. Upon a material change to a company under coverage, we may publish an update report on the website, but for our most contemporary commentary and opinions, please follow us on Twitter.